Predilation in TAVR and Myocardial Injury

Performing balloon predilation or valvuloplasty before a transcatheter aortic valve replacement (TAVR) may increase the incidence and magnitude of myocardial injury with new-generation balloon-expandable valves.

Predilatación en TAVI ¿Datos definitivos para no complicarse tomando decisiones?

Some papers argue in favor or against direct implantation, others remain neutral, but this research is the first one to express a different point of view.

Historically, the biggest fear about valvuloplasty performed prior to TAVR was stroke. Now, a new factor comes into the picture: myocardial injury.

The DIRECTAVI (Direct Transcatheter Aortic Valve Implantation), an open-label randomized study, aimed to demonstrate the noninferiority of direct implantation compared with systematic previous valvuloplasty with the SAPIEN 3 valve. Levels of troponin were assessed at baseline and a day after the procedure.

The primary endpoint was troponin elevation >15× the upper reference limit (14 ng/l).

Researchers also assessed the impact of myocardial injury on certain clinical events a month after the procedure. Such events include mortality, stroke, major bleeding, vascular complications, transfusion, kidney injury, heart failure, pacemaker implantation, and aortic regurgitation.


Read also: Regression of High-Risk Plaque with Lifestyle Changes.


Troponin test results from 211 individuals were available at baseline and a month after the procedure. The mean age for this patient population was 83 (78-87 years old).

The results for high-sensitivity troponin after the procedure were 124.9 ± 81.4 ng/l in the direct implantation group, and 170.4 ± 127.7 ng/L in the systematic predilation group (p = 0.007). Myocardial injury occurred in 12.2% of individuals with direct implantation, and in 27.9% of individuals in the prior valvuloplasty group (p=0.004).

Systematic valvuloplasty before TAVR almost tripled the rates of myocardial injury (hazard ratio [HR]: 2.8; 95% confidence interval [CI]: 1.4 to 5.8).


Read also: Asymptomatic Patients: The Key to Understand the Prevalence of the COVID-19 Pandemic.


The presence of myocardial injury was assessed in troponin laboratory tests and also in adverse events unfolding a month after the procedure (p = 0.03).

Conclusion

Conducting a systemic balloon valvuloplasty before transcatheter aortic valve replacement increases the incidence and magnitude of myocardial injury with new-generation balloon-expandable valves. Myocardial injury resulted in adverse events a month after the procedure. 

The findings of this trial suggest performing direct implantation of the S3 valve.

JAHA-120-018405free

Original Title: Myocardial Injury After Balloon Predilatation Versus Direct Transcatheter Aortic Valve Replacement: Insights From the DIRECTAVI Trial.

Reference: Mariama Akodad et al. J Am Heart Assoc. 2020;9:e018405. DOI: 10.1161/JAHA.120.018405.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...